3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
40
Triple Negative Breast Neoplasms
16
Carcinoma, Transitional Cell
14
Breast Neoplasms
14
Small Cell Lung Carcinoma
12
Urinary Bladder Neoplasms
11
Melanoma
10
Carcinoma, Hepatocellular
9
Neoplasms
8
Carcinoma, Renal Cell
8
Uterine Cervical Neoplasms
6
Neoplasm Metastasis
6
Lung Neoplasms
6
Colorectal Neoplasms
5
Ovarian Neoplasms
4
Lymphoma, Follicular
4
Lymphoma
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Prostatic Neoplasms
3
Leukemia, Myeloid, Acute
3
Cholangiocarcinoma
3
Brain Neoplasms
3
Stomach Neoplasms
2
Solid Tumors
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Kidney Neoplasms
2
Gallbladder Neoplasms
2
Fallopian Tube Neoplasms
2
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Advanced Unresectable or Metastatic Solid Malignancy
×
atezolizumab
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts